{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:40:12Z","timestamp":1789058412157,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.vaccine.2018.10.070","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T09:27:41Z","timestamp":1542965261000},"page":"7916-7922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany"],"prefix":"10.1016","volume":"36","author":[{"given":"Dorothea","family":"Matysiak-Klose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Santibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schwerdtfeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"von Bernuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Hengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Littmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Terhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6726-1614","authenticated-orcid":false,"given":"Sabine","family":"Wicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Mankertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Heininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.10.070_b0005","article-title":"Why are young adults affected? Estimating measles vaccination coverage in 20\u201334 year old germans in order to verify progress towards measles elimination","volume":"7","author":"Schuster","year":"2015","journal-title":"PLoS Curr"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.070_b0010","doi-asserted-by":"crossref","first-page":"e68909","DOI":"10.1371\/journal.pone.0068909","article-title":"Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009: a risk estimation","volume":"8","author":"Sch\u00f6nberger","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.10.070_b0015","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix302","article-title":"Subacute sclerosing panencephalitis: the devastating measles complication that might be more common than previously estimated","author":"Wendorf","year":"2017","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.070_b0020","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/01443610903104478","article-title":"The rationale for the use of measles post-exposure prophylaxis in pregnant women: a review","volume":"29","author":"Manikkavasagan","year":"2009","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.070_b0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0163-4453(03)00045-8","article-title":"Measles infection in pregnancy","volume":"47","author":"Chiba","year":"2003","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.070_b0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"30","key":"10.1016\/j.vaccine.2018.10.070_b0035","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1016\/j.vaccine.2014.05.022","article-title":"Vaccine use in primary immunodeficiency disorders","volume":"32","author":"Principi","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2018.10.070_b0040","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.1220098110","article-title":"STAT2 deficiency and susceptibility to viral illness in humans","volume":"110","author":"Hambleton","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"307","key":"10.1016\/j.vaccine.2018.10.070_b0045","doi-asserted-by":"crossref","first-page":"307ra154","DOI":"10.1126\/scitranslmed.aac4227","article-title":"Human IFNAR2 deficiency: lessons for antiviral immunity","volume":"7","author":"Duncan","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.10.070_b0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF01253810","article-title":"Passive prophylaxis of measles","volume":"16","author":"Perkins","year":"1965","journal-title":"Arch Gesamte Virusforsch"},{"issue":"9","key":"10.1016\/j.vaccine.2018.10.070_b0055","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4161\/hv.25311","article-title":"Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next","volume":"9","author":"Young","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.070_b0060","first-page":"4","article-title":"Measles vaccine gamma globulin in the prevention of cross infection with measles in an acute paediatric ward","volume":"18","author":"Glyn-Jones","year":"1972","journal-title":"Cent Afr J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.070_b0065","first-page":"202","article-title":"Use of concentrated human serum \u0263-globuline in the prevention and attenuation of measles","volume":"21","author":"Janeway","year":"1945","journal-title":"Bull NY Acad Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.070_b0070","first-page":"1214","article-title":"Relative prophylacic value of convalescent and immune adult measles serums","volume":"39","author":"Morales","year":"1930","journal-title":"Am J Dis Child"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.070_b0075","first-page":"401","article-title":"Prophylaxis of measles","volume":"32","author":"Toomey","year":"1926","journal-title":"Am J Dis Child"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.070_b0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/rmv.480","article-title":"Convalescent whole blood, plasma and serum in the prophylaxis of measles","volume":"15","author":"Zingher","year":"2005","journal-title":"Rev Med Virol"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2018.10.070_b0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1071\/NB08014","article-title":"The effectiveness of prophylaxis for measles contacts in NSW","volume":"20","author":"Sheppeard","year":"2009","journal-title":"NSW Public Health Bull"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.070_b0090","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1017\/S0950268814001344","article-title":"Prevention of measles spread on a paediatric ward","volume":"143","author":"Tapisiz","year":"2015","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.070_b0095","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0264-410X(94)90049-3","article-title":"Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus","volume":"12","author":"Christenson","year":"1994","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.070_b0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jit143","article-title":"Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage","volume":"208","author":"Waaijenborg","year":"2013","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.10.070_b0105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1086\/528993","article-title":"Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up","volume":"197","author":"Davidkin","year":"2008","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.10.070_b0110","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1473-3099(08)70282-2","article-title":"Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme","volume":"8","author":"Peltola","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.070_b0115","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/506363","article-title":"Measles-virus-neutralizing antibodies in intravenous immunoglobulins","volume":"194","author":"Audet","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.10.070_b0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2172-15-26","article-title":"Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study","volume":"15","author":"Nobre","year":"2014","journal-title":"BMC Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.070_b0125","first-page":"CD010056","article-title":"Post-exposure passive immunisation for preventing measles","author":"Young","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2018.10.070_b0130","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1099\/vir.0.013524-0","article-title":"Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope","volume":"90","author":"Finsterbusch","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.10.070_b9000","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1128\/JVI.75.9.4399-4401.2001","article-title":"Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor","volume":"75","author":"Ono","year":"2001","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.070_b0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0166-0934(81)90062-8","article-title":"Role of virus strain in conventional and enhanced measles plaque neutralization test","volume":"3","author":"Albrecht","year":"1981","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2018.10.070_b0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3181\/00379727-86-21073","article-title":"Propagation in tissue cultures of cytopathogenic agents from patients with measles","volume":"86","author":"Enders","year":"1954","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2018.10.070_b0145","unstructured":"Bentley M, Christian P, Heath A, WHO. Report on collaborative study to investigate the relationship between the 1st IRP and the 2nd and 3rd International Standards for Anti-Measles Serum\/Plasma, in both ELISA and PRNT. 2007."},{"key":"10.1016\/j.vaccine.2018.10.070_b0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2807\/1560-7917.ES.2017.22.34.30599","article-title":"Large measles outbreak introduced by asylum seekers and spread among the insufficiently vaccinated resident population, Berlin, October 2014 to August 2015","volume":"22","author":"Werber","year":"2017","journal-title":"Euro Surveill"},{"issue":"6641","key":"10.1016\/j.vaccine.2018.10.070_b0155","first-page":"732","article-title":"Gamma globulin in the prevention and attenuation of measles: controlled trials in day and residential nurseries","volume":"2","author":"Cockburn","year":"1950","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2018.10.070_b0160","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1067\/mpd.2001.113710","article-title":"Current efficacy of postexposure prophylaxis against measles with immunoglobulin","volume":"138","author":"Endo","year":"2001","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.070_b0165","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1172\/JCI101519","article-title":"Chemical, clinical, and immunological studies on the products of human plasma fractionation. Xii. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles","volume":"23","author":"Ordman","year":"1944","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2018.10.070_b0170","first-page":"41","article-title":"Gamma-globulin in the prevention and attenuation of measles: report of a subcommittee to the blood transfusion research committee of the medical research council","volume":"2","author":"Hartley","year":"1948","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.vaccine.2018.10.070_b0175","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1055\/s-0028-1132387","article-title":"Die prophylaktische Injektion von Normalserum als Masernschutz","volume":"49","author":"Salomon","year":"1923","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.070_b0180","first-page":"1","article-title":"Propylaxis of measles with convalescent serum: principal factors influencing the results","volume":"67","author":"Stillerman","year":"1944","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.vaccine.2018.10.070_b0185","unstructured":"Ramsay M, Manikkavasagan G, Brown KL. C. Post exposure prophylaxis for measles: revised guidance available at: <http:\/\/webarchivenationalarchivesgovuk\/20140714093111\/http:\/\/wwwhpaorguk\/webc\/HPAwebFile\/HPAweb_C\/1238565307587>. 2009."},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.070_b0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/21645515.2016.1234554","article-title":"Do Australian immunoglobulin products meet international measles antibody titer standards?","volume":"13","author":"Young","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2018.10.070_b0195","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/infdis\/162.5.1036","article-title":"Measles antibody: reevaluation of protective titers","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.10.070_b0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006454-199503000-00007","article-title":"Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal","volume":"14","author":"Samb","year":"1995","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2018.10.070_b0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vaccine.2007.10.046","article-title":"Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination","volume":"26","author":"Cohen","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.070_b0210","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1537-2995.1972.tb05893.x","article-title":"Antibody and immunoglobulin levels in regular blood donors","volume":"12","author":"Kouvalainen","year":"1972","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.070_b0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jviromet.2005.08.001","article-title":"Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay","volume":"131","author":"Cohen","year":"2006","journal-title":"J Virol Methods"},{"issue":"50","key":"10.1016\/j.vaccine.2018.10.070_b0220","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2008.08.074","article-title":"Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination","volume":"26","author":"Cohen","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.10.070_b0225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/jcm.33.4.811-815.1995","article-title":"Comparison of commercial enzyme-immunoassay kits with plaque reduction neutralization test for detection of measles-virus antibody","volume":"33","author":"Ratnam","year":"1995","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.10.070_b0230","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0022-3476(06)80114-9","article-title":"Interference of immune globulin with measles and rubella immunization","volume":"122","author":"Siber","year":"1993","journal-title":"J Pediatr"},{"issue":"10","key":"10.1016\/j.vaccine.2018.10.070_b0235","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00393-014-1396-x","article-title":"Immunization in children and adolescents with rheumatic and musculoskeletal diseases","volume":"73","author":"Minden","year":"2014","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.vaccine.2018.10.070_b0240","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/2011054a0","article-title":"Survival of measles virus in air","volume":"201","author":"De Jong","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.10.070_b0245","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics 1994;93(4):682\u20135.","DOI":"10.1542\/peds.93.4.682"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18314555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:29:16Z","timestamp":1759400956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18314555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":50,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0264410X18314555"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.10.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}